Literature DB >> 7525185

The management of follicular lymphoma.

A Z Rohatiner1, T A Lister.   

Abstract

Follicular lymphoma is demonstrably incurable with conventional treatment. A number of strategies have prolonged the duration of remission. However, none have convincingly improved survival. The following new treatment modalities are currently being evaluated: Interferon, given either alone, in combination with conventional chemotherapy or as maintenance therapy certainly has activity in follicular lymphoma, although its precise role remains to be defined. Myelo-ablative therapy with autologous bone marrow transplantation, with or without in vitro treatment of the marrow, is showing encouraging preliminary results, although longer follow-up is required. The use of radiolabelled monoclonal antibodies is an exciting area of research, with responses being observed in patients in whom other treatments have failed. The purine analogues, for example fludarabine, are an interesting class of new compound. Once more, these are proving to be useful when other treatments have failed. These four treatment modalities are critically appraised in the present paper.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7525185     DOI: 10.2165/00003495-199400476-00004

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  75 in total

1.  Autologous bone marrow transplantation in 69 patients with a history of low-grade B-cell non-Hodgkin's lymphoma.

Authors:  A S Freedman; J Ritz; D Neuberg; K C Anderson; S N Rabinowe; P Mauch; T Takvorian; R Soiffer; K Blake; B Yeap
Journal:  Blood       Date:  1991-06-01       Impact factor: 22.113

2.  Fludarabine phosphate (NSC 312878) infusions for the treatment of acute leukemia: phase I and neuropathological study.

Authors:  D R Spriggs; E Stopa; R J Mayer; W Schoene; D W Kufe
Journal:  Cancer Res       Date:  1986-11       Impact factor: 12.701

3.  Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis.

Authors:  T Takvorian; G P Canellos; J Ritz; A S Freedman; K C Anderson; P Mauch; N Tarbell; F Coral; H Daley; B Yeap
Journal:  N Engl J Med       Date:  1987-06-11       Impact factor: 91.245

4.  Total-body irradiation in the treatment of lymphocytic lymphoma.

Authors:  J T Chaffey; S Hellman; D S Rosenthal; W C Moloney
Journal:  Cancer Treat Rep       Date:  1977-09

5.  Irradiation in the local control of malignant lymphoreticular tumors (non-Hodgkin's malignant lymphoma).

Authors:  J D Cox; R H Koehl; W M Turner; F M King
Journal:  Radiology       Date:  1974-07       Impact factor: 11.105

6.  Fractionated radioimmunotherapy of B-cell malignancies with 131I-Lym-1.

Authors:  G L DeNardo; S J DeNardo; L F O'Grady; N B Levy; G P Adams; S L Mills
Journal:  Cancer Res       Date:  1990-02-01       Impact factor: 12.701

7.  A phase I toxicity, pharmacology, and dosimetry trial of monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma: effects of tumor burden and antigen expression.

Authors:  D A Scheinberg; D J Straus; S D Yeh; C Divgi; P Garin-Chesa; M Graham; K Pentlow; D Coit; H F Oettgen; L J Old
Journal:  J Clin Oncol       Date:  1990-05       Impact factor: 44.544

8.  Combination chemotherapy in lymphosarcoma and reticulum cell sarcoma.

Authors:  B Hoogstraten; A H Owens; R E Lenhard; O J Glidewell; L A Leone; K B Olson; J B Harley; S R Townsend; S Miller; C L Spurr
Journal:  Blood       Date:  1969-02       Impact factor: 22.113

9.  Interferon and murine leukemia. VII. Therapeutic effect of interferon preparations after diagnosis of lymphoma in AKR mice.

Authors:  I Gresser; C Maury; M Tovey
Journal:  Int J Cancer       Date:  1976-05-15       Impact factor: 7.396

10.  Malignant lymphoma. II Prognostic factors and response to treatment of 473 patients at the National Cancer Institute.

Authors:  T Anderson; V T DeVita; R M Simon; C W Berard; G P Canellos; A J Garvin; R C Young
Journal:  Cancer       Date:  1982-12-15       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.